Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of Skin Cancer|April 4, 2018
Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical ManagementAnna J Lomax, Jennifer Lim, Robert Cheng, et al.
Journal of Telemedicine and Telecare|October 18, 2021
Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemicAndrew O Parsonson, Peter Grimison, Michael Boyer, et al.
BMC Cancer|July 13, 2026
Curative-intent tri-modality treatment of de novo bone-only oligometastatic breast cancer: single-center patient outcomesJoseff Karl Fernandez, Georgia Harris, Boon Yang Jerome Leow, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|September 18, 2021
Considering the type and timing of breast reconstruction after mastectomy: Qualitative insights into women's decision-makingSarah Giunta, Rebekah Laidsaar-Powell, Lorna Huang, et al.
Blood|February 25, 2015
Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascadeSimbarashe Magwenzi, Casey Woodward, Katie S Wraith, et al.
Journal of Medical Genetics|October 26, 2021
Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to <i>FANCD1/BRCA2</i> during adulthood: description of an emerging phenotypeEmilia Ip, Catriona McNeil, Peter Grimison, et al.
AIDS (London, England)|May 11, 2018
Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latencyVanessa A Evans, Renée M van der Sluis, Ajantha Solomon, et al.
International Journal of Cancer|January 21, 2010
Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer developmentEmmy D G Fleuren, Sandra O'Toole, Ewan K Millar, et al.
Histopathology|April 8, 2015
Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testingChristina Selinger, Wendy Cooper, Trina Lum, et al.
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
Pageof 4